* Late-breaking presentation of BRAVO results and additional analyses from
    ALLEGRO study reinforce novel clinical profile of laquinimod
  * Pre-clinical evidence supports that laquinimod targets peripheral
    inflammation and key neurodegenerative processes occurring directly in the

Jerusalem,  Israel  and  Lund,  Sweden,  October  19, 2011 - Teva Pharmaceutical
Industries  Ltd. (NASDAQ:  TEVA) and  Active Biotech  (NASDAQ OMX  NORDIC: ACTI)
today  announced the presentation  of Phase III  clinical and pre-clinical data,
which  collectively demonstrate  that once-daily  oral laquinimod  modulates the
pathological  processes  of  multiple  sclerosis  to  impact  disease  activity,
disability  progression and brain volume loss. The data will be featured in more
than  20 scientific  posters  and  presentations  this  week  at the 5(th) Joint
Triennial  Congress of  the European  and Americas  Committees for Treatment and
Research   in  Multiple  Sclerosis  (ECTRIMS  and  ACTRIMS)  in  Amsterdam,  The

Findings  from the  second Phase  III study,  BRAVO, being  highlighted as late-
breaking  research, showed that at 24-months,  the primary endpoint of reduction
in  annualized relapse rates  (ARR) did not  reach statistical significance (0 =
0.075); however,  after applying a pre-specified sensitivity analysis to correct
for  meaningful imbalances  in baseline  characteristics (MRI) between treatment
groups, laquinimod significantly reduced ARR (21.3%, p = 0.026). Laquinimod also
demonstrated  a significant reduction  in the risk  of disability progression as
measured  by the Expanded Disability Status  Scale (EDSS) (33.5%, p = 0.044) and
in  MRI-measured  brain  volume  loss  (27.5%,  p  =<  0.0001). The  safety  and
tolerability profile of laquinimod was favorable.

New  exploratory  analyses  from  ALLEGRO,  the  first  Phase  III  study in the
laquinimod  clinical development  program, demonstrated  that laquinimod  had an
effect  on the rate  of severe relapses,  showing a 38 percent  reduction in the
annualized rate of relapses requiring hospitalization and a 27 percent reduction
in  those  requiring  intravenous  steroids.  Treatment with laquinimod was also
associated  with a  36 percent reduction  in the  risk for three month confirmed
EDSS progression (p=0.0122) and a 48 percent reduction in the risk for six month
confirmed  EDSS progression (p= 0.0023). Additionally, laquinimod had a positive
impact on patient-reported fatigue and cognitive functioning, as assessed by the
Modified  Fatigue Impact Scale (MFIS)  and the short-form (SF)-36 general health

"The  life-long, debilitating  nature of  multiple sclerosis and well-recognized
clinical  variability, underscore the  need for therapies  that can slow disease
progression  and improve patient treatment experience," said Professor Giancarlo
Comi,  Director of  the Department  of Neurology  and Institute  of Experimental
Neurology  at the  San Raffaele  Scientific Institute,  Vita-Salute San Raffaele
University,  Italy. "Both Allegro and  Bravo studies provide consistent evidence
of  a clear impact of Laquinimod on progression of disability and brain atrophy,
measures of the neurodegenerative process of MS. These effects on disease burden
together  with  the  effects  on  relapse  management,  the  convenience of oral
administration  and the  excellent safety  and tolerability  profile represent a
unique approach to the treatment of MS.

"Several  supportive pre-clinical studies being  presented further elucidate the
potential   novel   mechanisms  of  action  of  laquinimod,  which  target  both
neurodegeneration  occurring directly  in the  CNS and  peripheral inflammation,
said Wolfgang Brück, M.D., Director of Neuropathology at Georg-August-University
in  Goettingen, Germany. "The cuprizone and  EAE mouse model studies showed that
laquinimod  reduced demyelination, axonal damage  and resulted in dose-dependent
decreases in pro-inflammatory cytokines, further demonstrating that the compound
acts  directly on  resident CNS  cells to  decrease neurodegeneration  and brain
tissue loss."

"The data presented at ECTRIMS contribute to the growing body of scientific
evidence supporting the novel clinical profile of laquinimod," said Jon
Congleton, Senior Vice President and General Manager, Teva Neuroscience. "We are
excited by the prospect of laquinimod providing a treatment option that
addresses important attributes of RRMS therapy, namely reduction of disability
progression and irreversible tissue loss, without compromising convenience,
safety or tolerability."

Laquinimod is an oral, once-daily CNS-active immunomodulator with a novel
mechanism of action being developed for the treatment of MS. Laquinimod crosses
the blood brain barrier to potentially have a direct effect on resident CNS
inflammation and neurodegeneration. The global Phase III clinical development
program evaluating oral laquinimod in MS consists of two pivotal studies,
ALLEGRO and BRAVO. In the ALLEGRO study, laquinimod demonstrated a positive
impact on disease activity and disability progression, while maintaining a
favorable safety and tolerability profile.  In addition to the MS clinical
studies, laquinimod is currently in Phase II development for Crohn's disease and
Lupus, and is being studied in other autoimmune diseases.

MS is the leading cause of neurological disability in young adults. It is
estimated that more than 400,000 people in the United States are affected by the
disease and that two million people may be affected worldwide. Multiple
sclerosis is a degenerative disease of the central nervous system in which
inflammation and axonal damage and loss result in the development of progressive

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic drug
maker, with a global product portfolio of more than 1,300 molecules and a direct
presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 45,000 people around the world
and reached $16.1 billion in net sales in 2010.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visit www.activebiotech.comfor more information.

Teva's  Safe  Harbor  Statement  under  the  U. S. Private Securities Litigation
Reform Act of 1995:
This  release  contains  forward-looking  statements,  which express the current
beliefs   and   expectations   of  management.  Such  statements  are  based  on
management's  current beliefs and expectations and involve a number of known and
unknown risks and uncertainties that could cause our future results, performance
or  achievements  to  differ  significantly  from  the  results,  performance or
achievements  expressed or implied by such forward-looking statements. Important
factors  that  could  cause  or  contribute  to  such  differences include risks
relating  to: our ability  to successfully develop  and commercialize additional
pharmaceutical  products, the introduction of competing generic equivalents, the
extent  to which we  may obtain U.S.  market exclusivity for  certain of our new
generic  products  and  regulatory  changes  that  may prevent us from utilizing
exclusivity  periods, potential liability for sales of generic products prior to
a  final resolution of outstanding patent litigation, including that relating to
the  generic  version  of  Protonix®,  the  extent to which any manufacturing or
quality  control problems damage our reputation for high quality production, the
effects of competition on sales of our innovative products, especially Copaxone®
(including  potential generic and oral competition for Copaxone®), the impact of
continuing  consolidation  of  our  distributors  and  customers, our ability to
identify,  consummate  and  successfully  integrate  acquisitions (including the
acquisition of Cephalon), interruptions in our supply chain or problems with our
information  technology systems that adversely  affect our complex manufacturing
processes,  intense competition in our  specialty pharmaceutical businesses, any
failures  to comply with the complex Medicare and Medicaid reporting and payment
obligations,  our exposure to currency fluctuations  and restrictions as well as
credit  risks, the effects of reforms  in healthcare regulation, adverse effects
of  political or economical instability, major  hostilities or acts of terrorism
on  our significant worldwide operations,  increased government scrutiny in both
the  U.S. and Europe of  our agreements with brand  companies, dependence on the
effectiveness  of our patents and other protections for innovative products, our
ability  to achieve  expected results  through our  innovative R&D  efforts, the
difficulty  of predicting U.S. Food  and Drug Administration, European Medicines
Agency  and other regulatory authority  approvals, uncertainties surrounding the
legislative  and  regulatory  pathway  for  the  registration  and  approval  of
biotechnology-based  products, potentially significant impairments of intangible
assets  and  goodwill,  potential  increases  in  tax liabilities resulting from
challenges  to our intercompany arrangements,  our potential exposure to product
liability  claims to  the extent  not covered  by insurance,  the termination or
expiration   of   governmental   programs  or  tax  benefits,  current  economic
conditions,  any  failure  to  retain  key  personnel  or  to attract additional
executive  and managerial talent, environmental risks and other factors that are
discussed  in our  Annual Report  on Form  20-F and  other filings with the U.S.
Securities and Exchange Commission.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:
This press release contains certain forward-looking statements. Such forward-
looking statements involve known and unknown risks, uncertainties and other
important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from any
future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or publicly
release any revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press release.

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on October 19, 2011.

Teva IR:
Elana Holzman,Teva Pharmaceutical Industries Ltd.,972 (3) 926-7554
Kevin Mannix, Teva North America, (215) 591-8912

Teva PR:
Yossi Koren, Teva Pharmaceutical Industries Ltd., 972 (3) 926-7687
Denise Bradley, Teva North America, (215) 591-8974

Active Biotech:
Tomas Leanderson, Active Biotech AB, +46 46 19 20 95
Hans Kolam, Active Biotech AB, +46 46 19 20 44


This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE